AEON Biopharma (NYSE American: AEON) releases Q2 2025 results via 8-K

Rhea-AI Filing Summary

AEON Biopharma, Inc. furnished an update on its business by announcing financial results for the second quarter ended June 30, 2025. The company disclosed that these results were communicated through a press release dated August 12, 2025, which is included as Exhibit 99.1 to this Form 8-K.

The press release is treated as "furnished" rather than "filed" under the securities laws, which means it is not automatically subject to certain liability provisions and is not incorporated into other filings unless specifically referenced. No detailed financial figures are included in this report itself; those appear in the accompanying press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 08/12/2025 - 04:06 PM Learn about SEC filing dates

FAQ

What did AEON (AEON) announce in this Form 8-K?

AEON Biopharma, Inc. announced that it released its financial results for the second quarter ended June 30, 2025. These results are contained in a press release dated August 12, 2025, which is attached as Exhibit 99.1.

Where can investors find AEON (AEON) Q2 2025 financial details?

The detailed Q2 2025 financial information for AEON Biopharma, Inc. is in Exhibit 99.1, a press release dated August 12, 2025, that is furnished with this Form 8-K.

How are AEON’s Q2 2025 results treated under securities laws?

The information in Item 2.02, including Exhibit 99.1, is being furnished, not filed. It is not subject to Section 18 liability of the Exchange Act and is not incorporated into other filings unless specifically referenced.

What period does AEON Biopharma’s reported quarter cover?

The Form 8-K states that AEON Biopharma, Inc. announced financial results for the second quarter ended June 30, 2025.

Who signed AEON Biopharma’s August 12, 2025 Form 8-K?

The Form 8-K was signed on behalf of AEON Biopharma, Inc. by Robert Bancroft, Chief Executive Officer, dated August 12, 2025.

What exhibits are included with this AEON (AEON) Form 8-K?

The filing includes Exhibit 99.1, a press release dated August 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

0001837607false00018376072025-08-122025-08-12

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

​

Delaware		001-40021		85-3940478
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​

5 Park Plaza

Suite 1750

Irvine, CA 92614

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (949) 354-6499

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	​	AEON	​	NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

​

​

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On August 12, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

The information furnished in this Item 2.02 of this Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

​

​

​

Item 9.01. Financial Statement and Exhibits.

​

(d) Exhibits.

​

​

Exhibit No.							Description
​		​					​
99.1							Press Release, dated August 12, 2025.
104		​					Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
​	AEON Biopharma, Inc.
Date: August 12, 2025	By:	/s/ Robert Bancroft
​	​	Robert Bancroft
​	​	Chief Executive Officer ​

​

​

​